https://www.businesswire.com/news/home/20190507005195/en/ > DALLAS--(BUSINESS WIRE)--May 7, 2019--Peloton Therapeutics, Inc., a clinical-stage biopharmaceutical company advancing first-in-class oral medicines for cancer and other serious conditions, announced that Timothy P. Coughlin, former Chief Financial Officer of Neurocrine Biosciences, Inc., and Thilo Schroeder, Ph.D., Partner at Nextech Invest, Ltd. and former Peloton Board Observer, have been appointed to its Board of Directors. Steve Winick, J.D., Managing Director of Topspin Partners, who has been a director since 2016, has resigned from the Board. > “We thank Steve for his diligent service and are pleased to welcome these two distinguished leaders to our Board of Directors,” said John A. Josey, Ph.D., Peloton’s Chief Executive Officer. “Tim has been instrumental to the success of a high-growth clinical-stage organization and its transition to a commercial-stage company with successful FDA approvals in recent years. He brings substantive executive management experience in financial functions as well as healthcare expertise. Thilo, who has a deep understanding of our company and programs from his years as a Board Observer, brings considerable scientific and business acumen as an oncology company investor.”